Xufen Yu

Aug 6, 2024 | nature.com | Xufen Yu |Jian Jin

AbstractBreast cancer (BC) remains the second leading cause of cancer-related mortalities in women. Resistance to hormone therapies such as tamoxifen, an estrogen receptor (ER) inhibitor, is a major hurdle in the treatment of BC. Enhancer of zeste homolog 2 (EZH2), the methyltransferase component of the Polycomb repressive complex 2 (PRC2), has been implicated in tamoxifen resistance.

Aug 3, 2023 | nature.com | Julia Zhao |Zaigham Khan |Xufen Yu |Ravisankar Rajarethinam |Jian Jin |Augusto Villanueva | +7 more

AbstractHepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide. β-Catenin (CTNNB1)-mutated HCC represents 30% of cases of the disease with no precision therapeutics available. Using chemical libraries derived from clinical multi-kinase inhibitor (KI) scaffolds, we screened HCC organoids to identify WNTinib, a KI with exquisite selectivity in CTNNB1-mutated human and murine models, including patient samples.

Jun 14, 2023 | pubs.rsc.org | Xufen Yu |Jian Jin

Chemically induced degradation of epigenetic targets† Md Kabir,a   Xufen Yu,a   H. Ümit Kaniskan *a  and  Jian Jin *a   Abstract Proteolysis-targeting chimeras (PROTACs) are heterobifunctional small molecules that induce the ternary complex formation between a protein-of-interest (POI) and an E3 ligase, leading to targeted polyubiquitination and degradation of the POI.

Feb 6, 2023 | newsbreak.com | Xufen Yu

Our new Privacy Policy will go into effect on January 1st, 2023. Follow the link to read our updated Privacy Policy

Feb 6, 2023 | nature.com | Xufen Yu |Gang Wang

Author notesThese authors contributed equally: Xufen Yu, Jun Wang.